-- Mesoblast (ASX:MSB) achieved the recruitment target of at least 300 patients for a phase 3 clinical trial of rexlemestrocel-L for the treatment of chronic lower back pain associated with degenerative disc disease, according to a Wednesday filing with the Australian bourse.
The placebo-controlled study will randomize patients to a single intradiscal injection of the company's proprietary allogeneic stromal cell therapy or sham control for 12 months, with its primary endpoint being a significant difference in the reduction of lower back pain, per the filing.
The trial's secondary endpoints include improvements in function, quality of life, and cessation of pain medication including opioids.
The company expects to see top-line results in mid-2027.
Shares of Mesoblast gained nearly 5% in recent Wednesday trade.